Researchers find that total neoadjuvant therapy has a significant impact on survival for patients with borderline resectable or locally advanced PDAC.
Using data from the CPS-II, researchers determined a link between higher BMI in adults younger than 50 years and risk of pancreatic cancer.
[OncoTargets and Therapy] This review focuses on the value of using nal-IRI, toxicities, recent clinical experiences, and tools to improve outcomes for patients receiving gemcitabine-based therapy.
No evidence seen for benefits of pancreatic cancer screening, according to study data.
A study conducted in a single institution sought to measure the impact including an oncology nurse navigator in the healthcare team has on patient treatment and outcomes.